<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2445">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04716023</url>
  </required_header>
  <id_info>
    <org_study_id>18IC4688</org_study_id>
    <nct_id>NCT04716023</nct_id>
  </id_info>
  <brief_title>Physiology and Structure of the Small Airways in Patients With Chronic Airflow Obstruction or COVID-19</brief_title>
  <acronym>PASSPORT</acronym>
  <official_title>Physiology and Structure of the Small Airways in Patients With Chronic Airflow Obstruction or COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research project is to study small airways physiological function in&#xD;
      patients with chronic obstructive lung disease or COVID-19 and explore the relationship with&#xD;
      in-vivo microanatomical small airway structure as measured by OCT. Correlating endobronchial&#xD;
      assessment with multiple breath nitrogen washout and impulse oscillometry will allow the&#xD;
      characterisation of the relationship between small airway structural findings and these&#xD;
      validated investigations. A small volume lung wash, endobronchial brushings and the&#xD;
      collection of a limited number of endobronchial cryobiopsy samples will be performed to&#xD;
      better understand the endobronchial environment of the small airways through inflammatory&#xD;
      studies. Following the completion of any such work, residual samples will be stored in a&#xD;
      &quot;bio-bank&quot; to enable the completion of future work. Understanding the relationship with&#xD;
      symptom-based quality of life scoring questionnaires and a functional assessment of exercise&#xD;
      capacity will help elucidate the clinical impact of in-vivo small airways findings.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 23, 2019</start_date>
  <completion_date type="Anticipated">February 2, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 22, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Respiratory resistance at 5Hz - 20Hz (R5-R20) (kPa/l/s) related to airtrapping as determined by quantitative CT (Expiratory phase low attenuation area &lt;856 HU (%LAA &lt;856 HU)</measure>
    <time_frame>Baseline, pre-procedure</time_frame>
    <description>Impulse Oscillometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Respiratory reactance at 5Hz: X5 (kPa/l/s)</measure>
    <time_frame>Baseline, pre-procedure</time_frame>
    <description>Impulse Oscillometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reactance area: Ax (kPa/l/s)</measure>
    <time_frame>Baseline, pre-procedure</time_frame>
    <description>Impulse Oscillometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional residual capacity by MBNW: FRCgas (L)</measure>
    <time_frame>Baseline, pre-procedure</time_frame>
    <description>Multiple Breath Nitrogen Washout</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung clearance index: LCI</measure>
    <time_frame>Baseline, pre-procedure</time_frame>
    <description>Multiple Breath Nitrogen Washout</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilation heterogeneity conducting airways: Scond (L/s)</measure>
    <time_frame>Baseline, pre-procedure</time_frame>
    <description>Multiple Breath Nitrogen Washout</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilation heterogeneity acinar airways: Sacin (L/s)</measure>
    <time_frame>Baseline, pre-procedure</time_frame>
    <description>Multiple Breath Nitrogen Washout</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced expiratory volume in 1 second: FEV1 (L)</measure>
    <time_frame>Baseline, pre-procedure</time_frame>
    <description>Spirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced vital capacity: FVC (L)</measure>
    <time_frame>Baseline, pre-procedure</time_frame>
    <description>Spirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total lung capacity: TLC (L)</measure>
    <time_frame>Baseline, pre-procedure</time_frame>
    <description>Plethysmography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual volume: RV (L)</measure>
    <time_frame>Baseline, pre-procedure</time_frame>
    <description>Plethysmography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional residual capacity by plethysmography: FRCpleth (L)</measure>
    <time_frame>Baseline, pre-procedure</time_frame>
    <description>plethysmography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Airway mean luminal diameter (Dmean)</measure>
    <time_frame>Baseline, during the procedure</time_frame>
    <description>Optical Coherence Tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Airway inner lumen area (Ai)</measure>
    <time_frame>Baseline, during the procedure</time_frame>
    <description>Optical Coherence Tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Airway wall area (Aw), airway wall percentage (Aw%) as determined by [Aw/(Ai + Aw) × 100%]</measure>
    <time_frame>Baseline, during the procedure</time_frame>
    <description>Optical Coherence Tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Air trapping - expiratory phase low attenuation area &lt;856 HU (%LAA &lt;856 HU)</measure>
    <time_frame>Baseline, pre-procedure</time_frame>
    <description>Quantitative CT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified MRC dyspnoea score</measure>
    <time_frame>Baseline, pre-procedure</time_frame>
    <description>Patient reported outcome measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>St George's Respiratory Questionnaire Score</measure>
    <time_frame>Baseline, pre-procedure</time_frame>
    <description>Patient reported outcome measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma-related Quality of Life Questionnaire (AQLQ) (if asthmatic)</measure>
    <time_frame>Baseline, pre-procedure</time_frame>
    <description>Patient reported outcome measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Control Questionnaire (ACQ) (if asthmatic)</measure>
    <time_frame>Baseline, pre-procedure</time_frame>
    <description>Patient reported outcome measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-minute walk distance (m)</measure>
    <time_frame>Baseline, pre-procedure</time_frame>
    <description>6-minute walk distance (m)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory: Inflammatory and pathological studies of airways brush, wash and cryobiopsy samples</measure>
    <time_frame>Baseline, during the procedure</time_frame>
    <description>Laboratory based scientific studies</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Copd</condition>
  <condition>COVID-19</condition>
  <condition>Asthma</condition>
  <condition>Small Airways Disease</condition>
  <arm_group>
    <arm_group_label>Chronic Airflow obstruction / COVID-19</arm_group_label>
    <description>Patients with either chronic airflow obstruction of COVID-19</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects over the age of 16 with either chronic airflow obstruction or COVID-19&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 16 or over&#xD;
&#xD;
          2. Scheduled for bronchoscopy as part of clinical care or research protocol&#xD;
&#xD;
          3. No bleeding diathesis or therapeutic anticoagulation&#xD;
&#xD;
          4. COPD:&#xD;
&#xD;
               -  FEV1/FVC ratio &lt;70% or&#xD;
&#xD;
        Asthma:&#xD;
&#xD;
          -  Diagnosed by standard clinical methods&#xD;
&#xD;
          -  Post-bronchodilator FEV1 ≥60% predicted or COVID-19 infection or previous COVID-19&#xD;
             infection (confirmed as per local guidelines)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unable to provide informed consent&#xD;
&#xD;
          2. Exacerbation of obstructive airways disease or respiratory infection requiring&#xD;
             systemic antibiotics or corticosteroids in the 6 weeks prior to enrolment unless&#xD;
             suffering from COVID-19 infection and bronchoscopy is required for clinical reasons&#xD;
&#xD;
          3. Contra-indications to performing lung function testing&#xD;
&#xD;
               -  Aortic aneurysm &gt;6cm&#xD;
&#xD;
               -  Unstable cardiovascular disease (unstable angina, myocardial infarction or&#xD;
                  pulmonary embolism &lt;4 weeks prior)&#xD;
&#xD;
               -  Severe aortic stenosis&#xD;
&#xD;
               -  Pneumothorax&#xD;
&#xD;
               -  Cerebral aneurysm&#xD;
&#xD;
               -  Thoracic or abdominal surgery &lt;4 weeks prior&#xD;
&#xD;
          4. Contra-indications to passing oesophageal balloons&#xD;
&#xD;
               -  Oesophageal ulceration or varices&#xD;
&#xD;
               -  Sinusitis, recent nasal surgery or epistaxis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christopher M Orton, MBBS</last_name>
    <phone>02073518029</phone>
    <phone_ext>8029</phone_ext>
    <email>c.orton@rbht.nhs.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Royal Brompton</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher M Orton, MBBS</last_name>
      <phone>02073518029</phone>
      <phone_ext>8029</phone_ext>
      <email>c.orton@rbht.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>July 2, 2020</study_first_submitted>
  <study_first_submitted_qc>January 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2021</study_first_posted>
  <last_update_submitted>January 18, 2021</last_update_submitted>
  <last_update_submitted_qc>January 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

